转移性去势抵抗性前列腺癌多西他赛/泼尼松治疗失败后加用雌二醇氮芥的疗效和安全性:单中心回顾性研究

沈志远; 陶晶; 徐骏; 盛璐; 张正望; 张豪杰; 丁海雍; 钱伟庆; 孙忠全

doi:10.13201/j.issn.1001-1420.2020.03.003

转移性去势抵抗性前列腺癌多西他赛/泼尼松治疗失败后加用雌二醇氮芥的疗效和安全性:单中心回顾性研究

- 复旦大学附属华东医院泌尿外科(上海 200040)

详细信息

通讯作者: 孙忠全,E-mail:drzhongquan@sina.com

中图分类号: R737.25

收稿日期: 2018-08-25

Addition of estramustine to prednisone/docetaxel for patients with metastatic castration-resistant prostate cancer after P/D failure: a single-center experience

- Department of Urology, Huadong Hospital, Fudan University, Shanghai, 200040, China

More Information

Corresponding author: SUN Zhongquan, E-mail: drzhongquan@sina.com

Received Date: 25 August 2018

摘要

摘要: 目的:研究雌二醇氮芥/多西他赛/泼尼松(Estramustine/Prednisone/Docetaxel,E/D/P)联合治疗多西他赛/泼尼松(Prednisone/Docetaxel,D/P)失败后转移性去势抵抗性前列腺癌(mCRPC)患者的的疗效和安全性。方法:2005年11月~2015年7月我院40例D/P治疗失败的mCRPC患者接受了E/D/P联合治疗方案。将血清PSA水平降低50%作为主要终点。并对其化疗毒性进行评价。结果:所有患者接受了185个周期的E/D/P治疗。40例均符合安全性评价,35例符合疗效评价。总中位无生化进展生存期为17.1周,中位总生存期为85.7周,62.8%(22/35)的患者有治疗应答,E/D/P应答者的总生存期明显优于E/D/P无应答者(104.6周vs.65.1周)。尽管在15%的患者中有3~4级的嗜中性粒细胞减少症,但这种联合治疗方案总体上是可以耐受的。结论:回顾性资料表明,雌二醇氮芥能有效逆转多西他赛的耐药性,延长生存期。E/D/P联合治疗D/P失败后的mCRPC患者的治疗效果明显,且毒性可接受。
- 去势抵抗性前列腺癌 /
- 二线化疗 /
- 雌二醇氮芥 /
- 多西他赛 /
- 泼尼松
Abstract: Objective: To investigate the efficacy and safety of Estramustine/Prednisone/Docetaxel combination(E/P/D) as salvage chemotherapyforpatients with metastatic castration-resistant prostate cancer(mCRPC) after the failure of Prednisone/Docetaxel(P/D). Method: Forty mCRPC patients for whom P/D treatment had failed received E/P/D treatment between November 2005 to July 2015. A decrease of >50% in serum PSA level was set as the primary endpoint. The toxicity profiles were also reviewed. Rusult: Patients received a total of 185 cycles of E/P/D treatment. All 40 cases were eligible for safety analysis, and 35 cases were eligible for the evaluation of treatment effect. The media nbiochemical progression-free survival was 17.1 weeks, and the media noverall survival was 85.7 weeks. Furthermore, 62.8%(22/35) patients had treatment response, and the overall survival in responders to E/P/D therapy was significantly better than that innonresponders. Despite grade 3-4 neutropenia in 15% of patients, this combination was in general tolerable.Conclusion: Retrospective dataindicated estramustine effectively reverse resistance of docetaxel and prolonging survival. E/P/D combination is relatively active with acceptable toxicity profile as salvage treatment for mCRPC patientsafter the failure of P/D.
- castration-resistant prostate cancer /
- second line chemotherapy /
- estramustine /
- docetaxel /
- prednisone

HTML全文

参考文献(19)

[1]	郝斌,马志方.去势抵抗性前列腺癌化疗及其新进展[J].临床泌尿外科杂志,2015,30(1):83-87.
[2]	Tannock IF,de Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351(15):1502-1512.
[3]	Petrylak DP,Tangen CM,Hussain MH,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J].N Engl J Med,2004,351(15):1513-1520.
[4]	周世豪,陈国俊.去势抵抗性前列腺癌的治疗进展[J].临床泌尿外科杂志,2017,32(3):241-244.
[5]	Sweeney CJ,Chen YH,Carducci M,et al.Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer[J].N Engl J Med,2015,373(8):737-746.
[6]	Jordan MA.Mechanism of action of antitumor drugs that interact with microtubules and tubulin[J].Curr Med Chem Anticancer Agents,2002,2(1):1-17.
[7]	Sinibaldi VJ,Carducci MA,Moore-Cooper S,et al.Phase Ⅱ evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma[J].Cancer,2002,94(5):1457-1465.
[8]	Caffo O,Sava T,Comploj E,et al.Docetaxel,with or without estramustine phosphate,as first-line chemotherapy for hormone-refractory prostate cancer:results of a multicentre,randomized phase Ⅱ trial[J].BJU Int,2008,102(9):1080-1085.
[9]	Eymard JC,Priou F,Zannetti A,et al.Randomized phaseⅡ study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer[J].Ann Oncol,2007,18(6):1064-1070.
[10]	Fizazi K,Le Maitre A,Hudes G,et al.Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer:a meta-analysis of individual patient data[J].Lancet Oncol,2007,8(11):994-1000.
[11]	Common Terminology Criteria for Adverse Events(CTCAE).https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf[Z].2017.
[12]	Scher H I,Morris M J,Stadler W M,et al.Trial Design and Objectives for Castration-Resistant Prostate Cancer:Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3[J].J Clin Oncol,2016,34(12):1402-1418.
[13]	Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[14]	Ross RW,Beer TM,Jacobus S,et al.A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel[J].Cancer,2008,112(3):521-526.
[15]	de Bono JS,Oudard S,Ozguroglu M,et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J].Lancet,2010,376(9747):1147-1154.
[16]	Magadoux L,Isambert N,Plenchette S,et al.Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer(review)[J].Int J Oncol,2014,45(3):919-928.
[17]	Oudard S,Banu E,Beuzeboc P,et al.Multicenter randomized phaseⅡ study of two schedules of docetaxel,estramustine,and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer[J].J Clin Oncol,2005,23(15):3343-3351.
[18]	孙忠全,丁海雍,张正望,等.多西他赛加泼尼松3周方案失败后联合雌二醇氮芥治疗激素难治性前列腺癌[J].世界肿瘤杂志,2008,7(1):13-15.
[19]	Caffo O,Sava T,Comploj E,et al.Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone[J].Urol Oncol,2010,28(2):152-156.